https://orcid.org/0000-0001-7589-2144
Figures & data
Table 1 Demographics of Participants in the TASCS Sample at Baseline Who Had Blood Eosinophil Counts Recorded, Stratified by Eosinophilic Status (≥300 Cells/µL) and Treatment Group
Figure 1 Forest plot describing the incidence rate ratios (95% CI) of acute exacerbations of chronic obstructive pulmonary disease between prednisone & theophylline and pooled placebo treatment arms in participants with blood eosinophil counts of <300 and ≥300 cells/µL, derived from a multi-level mixed effects model.
Figure 2 Adjusted annualised rates of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) between prednisone & theophylline (PrT) and pooled placebo (PP) in participants with blood eosinophil counts ≥300 cells/µL derived from a fixed effects model. *p <0.05.
Figure 3 Kaplan-Meier plot of time to first moderate–severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in participants with blood eosinophil counts ≥300 cells/µL in the prednisone & theophylline and pooled placebo treatment groups.
Table 2 Secondary Outcomes (Means, 95% CI) at Study Completion by Treatment Groups (Pooled Placebo and Prednisone & Theophylline) in Participants with Blood Eosinophil Counts ≥300 Cells/µL
Table 3 Baseline Univariate Predictors of a Blood Eosinophil Count of ≥300 Cells/µL in the TASCS Trial Sample